Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.35 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10115363 | 1.00 | ALDH1A1 (0.40) | ALDH1A1KMT2AMEN1HTR1AHDAC6 | |
| SCHEMBL12882821 | 0.89 | KMT2A (0.45) | ALDH1A1KMT2AMEN1HTR1AHDAC6 | |
| SCHEMBL10115340 | 0.89 | KMT2A (0.45) | ALDH1A1KMT2AMEN1HTR1AHDAC6 | |
| SCHEMBL10115093 | 0.86 | ALDH1A1 (0.40) | ALDH1A1KMT2AMEN1HDAC6USP2 | |
| SCHEMBL13204526 | 0.86 | ALDH1A1 (0.40) | ALDH1A1KMT2AMEN1HDAC6USP2 | |
| SCHEMBL17090056 | 0.85 | GRIA1 (0.41) | HTR1ABRD4GRIA1 | |
| SCHEMBL13564993 | 0.85 | GRIA1 (0.41) | HTR1ABRD4GRIA1 | |
| SCHEMBL10115306 | 0.84 | GAA (0.41) | ALDH1A1KMT2AMEN1HTR1AHDAC6 | |
| SCHEMBL10115381 | 0.84 | MAPT (0.48) | ALDH1A1HTR1AHDAC6USP2GAA | |
| SCHEMBL10113352 | 0.84 | MAPT (0.48) | ALDH1A1HTR1AHDAC6USP2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781461-B2 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2010-08-24 | — | — | US | disclosed |
| US-7265130-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-7265130-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-20070015762-A1 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2007-01-18 | — | — | US | disclosed |
| US-20070015762-A1 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015762-A1 | NPY Y5 antagonist | NPY5R, NPY1R, NPY2R | ALDH1A1 4558/4885KMT2A 2912/4885MEN1 2876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.